Teva Pharma (TEVA) Gets Favorable Ruling on COPAXONE vs. Mylan (MYL) in the U.K.

Article Stock Quotes (2) Comments (0)

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced that the United Kingdom High Court of Justice issued a decision in favor of Teva in a patent litigation proceeding against Generics (UK) Limited, a subsidiary of Mylan Laboratories Inc. (Nasdaq: MYL), on July 11, 2012. Generics (UK) Limited commenced the proceeding in the UK to seek the revocation of European Patent (UK) 762,888, a patent for COPAXONE (glatiramer acetate injection) expiring May 23, 2015, and to obtain a declaration that its proposed generic version of COPAXONE® would not infringe the ‘888 patent. The High Court specifically determined that the asserted claims of the ‘888 patent were valid, and also declined to issue a declaration that Generics UK’s proposed generic version of COPAXONE® would not infringe the ‘888 patent.

Any potential generic version of COPAXONE would require a marketing authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) before it could be commercialized.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Intuitive Surgical (ISRG) Jury Reaches Positive Verdict in Robot Case; Shares Rise
• Tempur-Pedic (TPX) is Now 'Tempur Sealy International'
• Sprint (S), SoftBank Receive Final State Regulatory Approval in Proposed Deal

Create E-mail Alert Related Categories

Corporate News, FDA, Litigation

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?